Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval
September 13, 2023 03:00 ET | Rentschler Biopharma SE
UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapyHighly experienced team ready to support ATMP innovators at all stagesOffering comprehensive range of...
Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease
June 01, 2023 05:09 ET | Rentschler Biopharma SE
Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...
Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility
November 30, 2022 07:00 ET | Autolus Therapeutics plc
LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma adds highly experienced executive to team and provides update on progress at Rentschler ATMP
June 13, 2022 10:00 ET | Rentschler Biopharma SE
Company hires Kassim Kolia, as Vice President, Business Development to grow cell and gene therapy businessStevenage ATMP site projected to be client ready for process development in late 2022 ...